The six-month data on Cabtreo (clindamycin phosphate 1.2%, adapalene 0.15%, benzoyl peroxide (BPO) 3.1%) is in, and the triple-combination topical gel continues to produce meaningful improvements in acne.
Ortho Dermatologics’ Cabtreo demonstrated significant and continued improvements in acne lesions, scarring, Post-Inflammatory Hyperpigmentation (PIH), Post-Inflammatory Erythema (PIE), and quality of life across 24 weeks of once-daily treatment, according to new data shared at the 2025 Annual Meeting of the American Academy of Dermatology.
Approximately two-thirds of participants achieved treatment success. At week 24, there was an 89% reduction from baseline in inflammatory lesions and a 70% reduction in noninflammatory lesions, the study showed. There were significant reductions from baseline in facial scarring and PIH by Weeks 12 and 8, respectively. Moreover, the gel was well-tolerated, and no adverse events/experiences occurred in this single-center study.
The bottom line? “Cabtreo is appropriate for long-term topical treatment of acne vulgaris,” the researchers conclude.
